GET DAILY SIGNALSJohnson & Johnson (JNJ) Q3 2026 Earnings: Revenue Beat and Raised Guidance Stand Out
Key Takeaways
- Johnson & Johnson reported third-quarter 2026 revenue of $25.4 billion, up 5.9% year over year and slightly ahead of the roughly $25.38 billion consensus.
- Adjusted EPS (earnings per share) came in at $2.59, beating the $2.53 estimate, though down 7.5% from $2.80 a year earlier on acquisition-related costs.
- Reported GAAP (Generally Accepted Accounting Principles) EPS was just $0.09, weighed down by a one-time charge tied to the proposed talc litigation resolution and recent M&A (mergers and acquisitions) activity.
- Innovative Medicine sales rose 7.7% to $16.8 billion, while the MedTech (medical technology) division grew only 2.5% to $8.6 billion, missing some forecasts.
- Management raised full-year 2026 guidance to $101.0–$101.4 billion in revenue and adjusted EPS of $11.05–$11.15.
Why This Quarter Matters for JNJ
Johnson & Johnson stands as a key indicator for the broader healthcare sector, with operations spanning pharmaceuticals and medical devices. Its third quarter, which ended September 27, 2026, carries added weight because the company is on track to surpass $100 billion in annual revenue for the first time in its 140-year history. The results also highlight how well JNJ is managing a major portfolio shift: defending against biosimilar competition to the blockbuster drug Stelara while building momentum in newer medicines such as Tremfya, Caplyta, and Carvykti. At the same time, investors are watching whether the MedTech business can regain traction after mixed results, making this quarter an important checkpoint for the company’s longer-term direction. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Numbers
For the third quarter of 2026, Johnson & Johnson reported worldwide sales of $25.4 billion, an increase of 5.9% from $23.99 billion in the prior-year period. On an operational basis, which excludes the impact of currency translation, sales grew 6.0%. The result edged past the analyst consensus of about $25.38 billion.
Adjusted EPS of $2.59 exceeded the $2.53 consensus estimate by $0.06, but declined 7.5% from $2.80 a year earlier. The decline reflects roughly $7 billion in expenses related to the acquisition of Firefly Bio and a strategic collaboration with Sail Biomedicines. Reported net earnings fell 95.9% to $210 million, with diluted EPS of $0.09, driven largely by a one-time charge of about $5.8 billion for the proposed resolution of ovarian talc litigation.
Segment results were mixed. Innovative Medicine generated $16.8 billion in sales, up 7.7% reported and 7.9% operationally, led by strong demand for oncology and neuroscience products. MedTech revenue rose 2.5% to $8.6 billion, helped by cardiovascular products including electrophysiology devices and Shockwave, but slowed by weaker international demand. U.S. sales climbed 9.1% to $15.0 billion, while international sales grew just 1.5% to $10.4 billion.
Reflecting strong operational performance, management raised its 2026 outlook. Full-year reported sales are now expected in the range of $101.0–$101.4 billion (a $101.2 billion midpoint), with adjusted EPS of $11.05–$11.15, an increase of $0.06 at the midpoint to $11.10.
Market Reaction and Investor Focus
Despite beating headline estimates, JNJ shares fell following the report, sliding roughly 2.6% in premarket trading and extending losses early in the session. The muted-to-negative reaction reflected investor focus on the weaker-than-expected MedTech performance and soft international growth rather than the pharmaceutical beat. All four MedTech segments — cardiovascular, orthopedics, surgery, and vision — underperformed analyst expectations, while management flagged pressure from Middle East disruptions, European spending shifts, and volume-based procurement in China. The raised guidance was welcomed, but the market’s attention remained on the slower-growing device business and the large one-time charges that compressed reported earnings.
Looking Ahead at Key Catalysts
Looking ahead, Johnson & Johnson enters the fourth quarter with momentum in its pharmaceutical franchise but work to do in MedTech. Management reiterated confidence in a path to double-digit growth by the end of the decade, and signaled that several near-term catalysts could shape investor sentiment.
One area to watch is the continued ramp of newer medicines. Tremfya, Caplyta, Carvykti, and Rybrevant are all growing strongly and are expected to help offset Stelara’s decline as biosimilar competition intensifies. The company also highlighted regulatory progress, including U.S. authorization for the OTTAVA robotic surgical system and approval of Imavvy for warm autoimmune hemolytic anemia.
On the device side, investors will monitor whether international headwinds ease and whether Abiomed’s heart-pump business returns to growth. Management indicated it is weighing a potential separation of its orthopedics business, with more detail expected at a December 8 Enterprise Business Review, where 2027 guidance may also be addressed.
Finally, the talc litigation resolution and the dilution from recent M&A remain important items to track, as they will continue to influence reported versus adjusted results in the quarters ahead.
Using Tickeron’s AI Tools in My Research
In my analysis of earnings movers like Johnson & Johnson, I often turn to Tickeron’s AI-powered tools to quickly compare performance across sectors. The AI Screener helps filter securities based on fundamentals, technical patterns, and AI-driven signals, making it easier to identify opportunities in healthcare and beyond without manual effort. It has become a useful part of my routine for staying on top of portfolio shifts and industry trends.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
JNJ's RSI Oscillator ascends from oversold territory
The RSI Indicator for JNJ moved out of oversold territory on October 07, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 17 of the 30 cases the stock moved higher. This puts the odds of a move higher at 57%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on JNJ as a result. In 33 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 39%.
The Moving Average Convergence Divergence (MACD) for JNJ just turned positive on October 21, 2026. Looking at past instances where JNJ's MACD turned positive, the stock continued to rise in 20 of 47 cases over the following month. The odds of a continued upward trend are 43%.
JNJ moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for JNJ crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 41%.
Following a +2.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 163 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
JNJ broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JNJ entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 26 (best 1 - 100 worst), indicating outstanding price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.673) is normal, around the industry mean (-1.476). P/E Ratio (30.992) is within average values for comparable stocks, (21.871). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.020) settles around the average of (0.038) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an investment holding company with interests in health care products
Industry PharmaceuticalsMajor
Advertisement